Pharmaceutical Amorphous Nanoparticles.
There has been a tremendous revolution in the field of nanotechnology, resulting in the advent of novel drug delivery systems known as nanomedicines for diagnosis and therapy. One of the applications is nanoparticulate drug delivery systems which are used to improve the solubility and oral bioavailability of poorly soluble compounds. This is particularly important because most of the molecules emerging from the drug discovery pipeline in recent years have problems associated with solubility and bioavailability. There has been considerable focus on nanocrystalline materials; however, amorphous nanoparticles have the advantage of synergistic mechanisms of enhancing dissolution rates (due to their nanosize range and amorphous nature) as well as increasing supersaturation levels (due to their amorphous nature). An example of this technology is NanomorphTM, developed by Soliqus/Abbott, wherein the nanosize drug particles are precipitated in an amorphous form in order to enhance the dissolution rate. This along with other simple and easily scalable manufacturing techniques for amorphous nanoparticles is described. In addition, the mechanisms of formation of amorphous nanoparticles and several physicochemical properties associated with amorphous nanoparticles are critically reviewed.
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut 06269.
Rajan
R
Jog
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut 06269. Electronic address: d.burgess@uconn.edu.
Diane J
DJ
Burgess
D000818:Animals; D025924:Chromatography, Supercritical Fluid / Q000295:instrumentation / Q000379:methods; D003460:Crystallization; D004337:Drug Carriers / Q000737:chemistry*; D055664:Electrochemical Techniques / Q000295:instrumentation / Q000379:methods; D004867:Equipment Design; D006801:Humans; D053758:Nanoparticles / Q000737:chemistry*; D036103:Nanotechnology / Q000295:instrumentation / Q000379:methods*; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000737:chemistry; D010599:Pharmacokinetics; D012995:Solubility; D013010:Sonication / Q000295:instrumentation / Q000379:methods
D004337:Drug Carriers; D004364:Pharmaceutical Preparations
X-ray diffraction; amorphous; bioavailability; calorimetry; dissolution; nanocrystalline; nanoparticles; solid state; solubility; stability